Professor Jack Cuzick

CBE, PhD, FRS, FMedSci, FRCP (hon)
Director, Wolfson Institute of Preventive Medicine
Centre Lead, Research Theme Lead
Research Focus

I am the Director of Wolfson Institute of Preventive Medicine and also Head of Centre for Cancer Prevention. My current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening.

Key Publications

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol (2015) 16(1):67-75. PMID: 25497694

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet (2014) 383(9922):1041-8. PMID: 24333009

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Onc (2011) 12(3):245-255. PMID: 21310658

A breast cancer prediction model incorporating familial and personal risk factors. Statist Med (2004) 23: 1111-1130. PMID: 15057881

Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 362: 1871-1876. PMID: 14667741

Major Funding
  • 2018-2023- CRUK, Catalyst, £1.4M
  • 2017-2020- Barts Charity, Preventative Neurology, £1.5M
  • 2014-2019- CRUK, Cancer Prevention, £6.9M
  • 2007-2019- CRUK, IBIS II, £2M
Other Activities
  • Fellow of the Academy of Medical Sciences
  • Fellow of the Royal Society
  • Science Strategy Committee member for Breast Cancer Now
  • Research Strategy Group member for Prostate Cancer UK
Research

I am currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. I have worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumours as an indicator of its potential chemopreventive role. I demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness.

I am involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer.

I am the statistician for several major breast cancer trials and maintain an active interest in developing new statistical methodology, especially in the area of adjustments for non-compliance and cross-over, and multi-arm clinical trials.

Other Activities
  • Fellow of the Academy of Medical Sciences
  • Fellow of the Royal Society
  • Science Strategy Committee member for Breast Cancer Now
  • Research Strategy Group member for Prostate Cancer UK
Major Funding
  • 2018-2023- CRUK, Catalyst, £1.4M
  • 2017-2020- Barts Charity, Preventative Neurology, £1.5M
  • 2014-2019- CRUK, Cancer Prevention, £6.9M
  • 2007-2019- CRUK, IBIS II, £2M
Recent Publications

Methylation of HPV 16 and EPB41L3 in oral gargles: Associations with oropharyngeal cancer detection and tumor characteristics Giuliano AR, Nedjai B, Lorincz AT et al. International Journal of Cancer (2020) 146(7) 1018-1030

Validation of the OncoMASTR risk score in estrogen receptor–positive/HER2-negative patients: A TransATAC study Buus R, Sestak I, Barron S et al. Clinical Cancer Research (2020) 26(7) 623-631

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Cuzick J, Sestak I, Forbes JF et al. Lancet (2020) 395(2) 117-122
https://www.ncbi.nlm.nih.gov/pubmed/31839281

Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk Dobson R, Jitlal M, Marshall CR et al. Annals of Neurology (2020) (7)

Measurement challenge: Protocol for international case-control comparison of mammographic measures that predict breast cancer risk Dench E, Bond-Smith D, Darcey E et al. BMJ Open (2019) 9(7)

Impact of screening on cervical cancer incidence: A population-based case-control study in the United States. Landy R, Sasieni PD, Mathews C et al. Int J Cancer (2019) (2)
https://www.ncbi.nlm.nih.gov/pubmed/31837006

Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool. Phillips K-A, Liao Y, Milne RL et al. JNCI Cancer Spectr (2019) 3(2) pkz066
https://www.ncbi.nlm.nih.gov/pubmed/31853515

European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. Biganzoli L, Marotti L, Cardoso M-J et al. Breast Care (2019) 14(1) 359-365
https://www.ncbi.nlm.nih.gov/pubmed/31933581

The Parkinson's Disease Mendelian Randomization Research Portal Noyce AJ, Bandres-Ciga S, Kim J et al. Movement Disorders (2019) 34(7) 1864-1872

Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. Castle PE, Adcock R, Cuzick J et al. Arch Pathol Lab Med (2019) (2)
https://www.ncbi.nlm.nih.gov/pubmed/31718233

For additional publications, please click here
Biography

I received my BSc in Mathematics and Physics from Harvey Mudd College, Claremont, California. I then studied an MSc in Mathematics at the University of London. I obtained my PhD in Mathematics from Claremont Graduate School, Claremont, California.

I was appointed John Snow Professor of Epidemiology at Queen Mary University of London. In 2017, I was awarded a CRUK Lifetime Achievement Award and a CBE.

Upcoming Events
  1. The London Pancreas Workshop 2020

    May 1 @ 9:30 am - 4:30 pm
  2. 2020 Circulating Cancer Biomarker Symposium

    May 4 @ 9:00 am - 5:30 pm
© 2013 ~ 2020 Cancer Research UK Barts Centre